ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

NEXIUM IV
Hyperacidity, GERD, and ulcers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

NEXIUM IV Rx

Generic Name and Formulations:
Esomeprazole (as sodium) 20mg, 40mg; per vial; pwd for IV inj after reconstitution or for infusion after reconstitution and dilution.

Company:
AstraZeneca Pharmaceuticals

Therapeutic Use:

Indications for NEXIUM IV:

Short-term (up to 10 days) alternative to oral therapy for GERD with erosive esophagitis. Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy in adults.

Adult:

GERD: Inject IV over ≥3 mins or infuse IV over 10–30 mins. ≥18yrs: 20–40mg once daily for ≤10 days; switch to oral form when feasible. Severe hepatic impairment: max 20mg/day. Risk reduction: initially 80mg IV over 30 mins, then 8mg/hr continuous infusion over 71.5hrs; switch to oral form when feasible. Hepatic impairment (mild-to-moderate): max continuous infusion at 6mg/hr; (severe): max 4mg/hr.

Children:

Infuse IV over 10–30 mins. <1 month: not recommended. 1 month–<1yr: 0.5mg/kg. 1yr–17yrs: <55kg: 10mg; ≥55kg: 20mg.

Warnings/Precautions:

Symptomatic response does not preclude gastric malignancy. Discontinue if acute interstitial nephritis, cutaneous/systemic lupus erythematosus occurs. Long-term therapy (eg, >3yrs) may lead to malabsorption or deficiency of Vit.B12. Use lowest dose for shortest duration appropriate to condition. Increased risk of osteoporosis-related fractures (hip, wrist, or spine) with long-term and multiple daily dose PPI therapy. Monitor magnesium levels with long-term therapy. Pregnancy. Nursing mothers.

Interactions:

Concomitant St. John's wort, rifampin, atazanavir, nelfinavir: not recommended. May potentiate saquinavir; monitor and consider reducing saquinavir dose. May alter absorption of gastric pH-dependent drugs (eg, ketoconazole, iron salts, erlotinib, digoxin). Antagonizes clopidogrel; consider alternative anti-platelets. May affect drugs metabolized by CYP2C19. May potentiate tacrolimus, cilostazol (consider reduced dose), methotrexate (consider temporary withdrawal of PPI). Caution with drugs that may cause hypomagnesemia (eg, digoxin, diuretics); monitor. Monitor warfarin. May give antacids concomitantly. May cause false (+) results in diagnostic investigations for neuroendocrine tumors; discontinue esomeprazole 14 days prior to CgA level assessment.

See Also:

NEXIUM

NEXIUM for ORAL SUSPENSION

Pharmacological Class:

Proton pump inhibitor.

Adverse Reactions:

Headache, diarrhea, abdominal pain, nausea, flatulence, constipation, dry mouth, inj site reactions, dizziness, vertigo; rare: rash, allergic reactions, hypomagnesemia, possible C. difficile-associated diarrhea. Children: Also, somnolence, regurgitation, tachypnea, increased ALT.

Note:

See Biaxin for more information on clarithromycin. See Amoxil for more information on amoxicillin.

Metabolism:

Hepatic (CYP2C19, CYP3A4). 97% protein bound.

Elimination:

Renal (primarily), fecal.

Generic Availability:

Caps (YES); Susp, IV (NO)

How Supplied:

Caps—30, 90, 1000; Susp—30 packets/box; IV soln (single-use vial)—10

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs